|
| Status |
Public on Dec 31, 2022 |
| Title |
Inhibiting Androgen Receptor Splice Variants with Cysteine-Selective Irreversible Covalent Inhibitors to Treat Prostate Cancer |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
Prostate cancer (PCa) affects over 250,000 men in the US. Androgen Receptor (AR) signaling inhibitors are the mainstay therapeutics for PCa. Advanced PCa that expresses AR splice variants (AR-SVs) does not respond to current therapeutic strategies. In this manuscript, we uncovered the physicochemical properties of the intrinsically-disordered transactivation domain of AR and AR-SV and developed novel AR irreversible covalent antagonists (SARICA) to the transactivation domain for the treatment of advanced PCa. SARICAs were also used to identify a potential binding region in the AR and AR-SV transactivation domain.
|
| |
|
| Overall design |
22RV1 ATAC-Seq and RNA-Seq and LNCaP ATAC-Seq
|
| |
|
| Contributor(s) |
Narayanan R, Johnson D |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| Submission date |
Oct 12, 2022 |
| Last update date |
Jan 02, 2023 |
| Contact name |
Daniel Lee Johnson |
| E-mail(s) |
djohn166@uthsc.edu
|
| Phone |
9014483743
|
| Organization name |
UTHSC
|
| Department |
Molecular Informatics Core
|
| Street address |
71 S Manassas
|
| City |
Memphis |
| State/province |
Tennessee |
| ZIP/Postal code |
38163 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
| GPL30173 |
NextSeq 2000 (Homo sapiens) |
|
| Samples (18)
|
|
| Relations |
| BioProject |
PRJNA889781 |
Less...
More...